Skip to main navigation
Liquidia Logo
Skip to main content
Liquidia Logo

    Home

  • Home

    • About

  • About Liquidia
    • Overview
    • Leadership
    • Board of Directors

    • Products and Pipeline

  • Pipeline and Products
    • Pipeline
    • Commercial Products
    • PRINT® Technology
    • Publications

    • IR Nav

  • Investors
    • Overview
    • Press Releases
    • Events & Presentations
    • Stock Information
      • Analyst Coverage
      • Stock Quote & Chart
      • Historical Price Lookup
      • Investment Calculator
    • Corporate Governance
      • Documents & Charters
      • Leadership
      • Board of Directors
      • Committee Composition
    • SEC Filings
    • IR Resources
      • Investor FAQs
      • IR Contact
      • Email Alerts
      • Proxy Online

    • Careers

  • Careers
    • Overview
    • Jobs
    • Benefits
    • Core Values

    • Contact Us

  • Contact Us
    • Overview
    • Map/Directions

Event

IR Nav

Investors
  • Overview
  • Press Releases
  • Events & Presentations
  • Stock Information
    Analyst Coverage Stock Quote & Chart Historical Price Lookup Investment Calculator
  • Corporate Governance
    Documents & Charters Leadership Board of Directors Committee Composition
  • SEC Filings
  • IR Resources
    Investor FAQs IR Contact Email Alerts Proxy Online

The 2024 Wells Fargo Healthcare Conference

Sep 5, 2024 at 11:00 AM EDT

Click here for webcast

IR Tools

  • Print Page
  • Share
  • RSS
Liquidia Logo

419 Davis Drive, Suite 100, Morrisville, NC 27560
Tel +1 919-328-4400
Fax +1 919-328-4402

Socials

© 2024 Liquidia Corporation All Rights Reserved.

Liquidia Corporation is a biopharmaceutical company developing innovative therapies for patients with rare cardiopulmonary disease. The company’s current focus spans the development and commercialization of products in pulmonary hypertension and other applications of its proprietary PRINT® Technology. PRINT enabled the creation of Liquidia’s lead candidate, YUTREPIA™ (treprostinil) inhalation powder, an investigational drug for the treatment of pulmonary arterial hypertension (PAH) and pulmonary hypertension associated with interstitial lung disease (PH-ILD). The company is also developing L606, an investigational sustained-release formulation of treprostinil administered twice-daily with a next-generation nebulizer, and currently markets generic Treprostinil Injection for the treatment of PAH. To learn more about Liquidia, please visit https://www.liquidia.com.

Legal Nav

  • Legal
  • Privacy
  • Cookies
  • Social Media
  • Facebook
  • Twitter
  • LinkedIn